UNASSIGNED: As @entity1031 ( @entity1031 ) are common in @entity299 ( @entity299 ), adequate oral anticoagulation for prophylaxis or treatment of @entity1031 is important. Until now, mainly @entity2067 antagonists have been used in these @entity1 . The purpose of this study was to provide first data on the use of direct oral anticoagulants in @entity299 . This prospective, observational, and longitudinal study included 102 consecutive @entity299 , of whom 75 (37 @entity1 and 38 @entity1 ; mean age 50    13  years) could be analyzed. Most common CHD were pre-tricuspid shunts (n  = 31; 41%), complex CHD (n  = 16; 21%), left heart/ @entity886 (n  = 5; 6%), right-sided @entity299 (n  = 9; 13%), post-tricuspid shunts (n  = 3; 4%), and others (n  = 11; 15%). Five @entity1 had @entity848 and 3 @entity1 a Fontan circulation. Mean follow-up was 12    11  months. @entity3925 was administered in 55 @entity1 , @entity5424 in 13 and @entity3926 in 7 @entity1 for @entity1031 prophylaxis in @entity943 (n  = 57), @entity64 /transient @entity63 attacks (n  = 11), deep vein @entity715 (n  = 4), @entity1151 (n  = 1) and atrial thrombi (n  = 3). Some @entity1 had >1 indication for adequate oral anticoagulation. CHA2-DS2-VASc score was >= 2 in 23 (31%), and 9 (12%) had a HAS-BLED score >= 2. There were neither @entity715 events nor major side effects. In conclusion, direct oral anticoagulants appear to be safe and effective in @entity299 . Long-term follow-up is needed to substantiate these findings.

Usefulness of Direct Oral Anticoagulants in Adult XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity886 :: ('MESH:C563178', 'Disease') :: ['aortic valve anomalies'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['dabigatran'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['Rivaroxaban'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['TEE', 'thromboembolic events'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['apixaban'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac/pulmonary artery anomalies', 'adults with congenital heart disease', 'ACHD'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic or major bleeding', 'thrombosis'] @entity943 :: ('MESH:D001145', 'Disease') :: ['atrial arrhythmias'] @entity848 :: ('MESH:D003490', 'Disease') :: ['cyanosis']
@entity299 :: (MESH:D006331,Disease) :: ['Congenital Heart Disease']
